Sponsors (4)
The bill substantially increases drug‑pricing transparency and regulatory oversight—giving patients, plan sponsors, and agencies better tools to lower costs and spot abusive PBM practices—at the cost of sizeable compliance burdens, privacy risks, potential legal fights, and uneven effects that could disadvantage smaller market participants.
Patients, participants, and group health plans gain much clearer drug‑pricing transparency (rebates, net prices, spread pricing, drug‑level reports), enabling plans to identify overpayments and negotiate lower net drug costs that can reduce out‑of‑pocket spending and improve benefit design.
Plan sponsors, large employers, and federal agencies get standardized, machine‑readable reports and summary information, improving their ability to evaluate PBM contracts, detect high‑spend drugs or steering, and to enforce PBM practices.
Participants (especially patients with chronic conditions) may see lower out‑of‑pocket costs and better safety/affordability as greater visibility into rebates, fees, and manufacturer assistance pressures lower list/net prices and supports improved benefit design.
PBMs, health plans, and insurers (and ultimately employers and taxpayers) will face substantial new compliance and administrative costs to collect, process, and report detailed claims and pricing data, which could raise premiums, administrative expenses, or plan costs.
Participants and beneficiaries face increased privacy and reidentification risks because detailed claim‑ and participant‑level data will flow through more entities and reports despite HIPAA references, requiring costly safeguards and raising exposure concerns.
Smaller PBMs, affiliated pharmacies, small plan sponsors, and small employers will bear disproportionate burdens — facing contractual disruption, competitive pressure, or lacking resources to process or use the data — concentrating benefits among large, well‑resourced sponsors.
Based on analysis of 4 sections of legislative text.
Requires PBMs, group health plans, and issuers to disclose machine‑readable drug‑level pricing, payments, rebates, and utilization data and bans contracts that block those disclosures.
Official title: To amend the Public Health Service Act, the Employee Retirement Income Security Act of 1974, and the Internal Revenue Code of 1984 to increase oversight of pharmacy benefit management services, and for other purposes.
Introduced March 27, 2025 by Kristen McDonald Rivet · Last progress March 27, 2025
Establishes federal rules requiring pharmacy benefit managers (PBMs), group health plans, and group insurers to disclose detailed drug-level pricing, payments, rebates, and utilization data. It creates licensing/registration standards for PBMs, bans discriminatory PBM practices, extends nondiscrimination protections to covered health programs receiving federal assistance, and gives HHS authority to enforce and issue implementing rules. For plan years beginning 30 months after enactment, contracts entered or renewed must not block required disclosures; PBMs must provide semiannual (or quarterly on request) machine-readable plain-language reports to plans; plans and issuers must also report drug- and therapeutic-class-level spending and utilization to the federal government. A parallel tax-title provision imposes similar reporting obligations under the Internal Revenue Code.